跳至主要内容

Hit Identification in Drug Discovery

 Medicilon’s Chemistry department has more than 100 chemists, who are experienced in the cooperation with major domestic and international pharmaceutical and biotech companies. Our services cover a variety of research interests in novel drug research, including target validation, hits evaluation, lead optimization, candidate nomination, preclinical development and IND filing.


Medicilon has completed dozens of drug research projects for clients and successfully identified several drug candidates for clinical trials. Our team provides the following services:

  • Target Assessment – Drug Targets
  • HITs Identification
  • Lead Optimization
  • Clinical Candidate Nomination
  • Computer Aided Drug Design
  • SAR Study

Hit discovery technologies range from traditional high-throughput screening to affinity selection of large libraries, fragment-based techniques and computer-aided de novo design, many of which have been extensively reviewed. Development of quality leads using hit confirmation and hit-to-lead approaches present their own challenges, depending on the hit discovery method used to identify the initial hits.

Hit Identification Using Virtual Screening

For hit identification, some information about either the target protein or an active compound is necessary. In the case of a known structure of the protein, a virtual screening of compound libraries leads to virtual hits which will be synthesised and tested afterwards or tested immediately.

If the structure of the natural substrate is known, a ligand based approach will be accomplished. The computer searches for similar compounds and the resulting hits are checked for drug like properties.

Current screening methods in drug discovery include either phenotypic cellular assays with functional read‐outs, or biochemical assays requiring the generation of target‐expressing stable cell lines, and purification of target to screen against a compound library. Secondary and profiling assays are then used to determine compound cell permeability and cytotoxicity. This process can be extremely difficult for some targets such as those forming protein–protein interactions or membrane receptors.

Hit Identification Assay Features

– Protein target can be membrane bound, difficult to produce for standard biochemical assays, and difficult to purify;
– Hit and lead compounds and focused libraries can be screened against protein target within physiological environment;
– Compound cell permeability, specificity and cytotoxicity are assessed in one process;

– Process can be upscaled to screen hundreds of compounds in a few hours.

Hit Identification Assay Applications

  • Primary and secondary medium to high throughput screening in drug discovery
  • Target identification or validation for hit phenotypic screening

 

Contact Us 

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of hit identification in drug discovery and drug target identification methods. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...